GLP-1 and pregnancy: what patients need to know

GLP-1 receptor agonists are contraindicated in pregnancy. This is not a soft recommendation — it is a clear contraindication in the FDA-approved prescribing information for every GLP-1 medication used for weight management. Yet many patients start these drugs without a full understanding of what the contraindication means in practice, how long they need to wait before conceiving, or whether male partners should also stop treatment. This guide covers the clinical basis, the washout timelines, and the questions every patient of reproductive age should discuss with their prescriber.

Why GLP-1 medications are contraindicated in pregnancy

The contraindication is based on animal reproduction studies, not human clinical trial data. In animal studies, semaglutide and tirzepatide were associated with embryofetal toxicity, including structural abnormalities and early pregnancy loss, at clinically relevant exposures. Because no adequate and well-controlled studies exist in pregnant humans — and because weight loss offers no benefit during pregnancy and may cause fetal harm — the FDA classifies all GLP-1 RAs as contraindicated in pregnancy.

The prescribing information for Wegovy states: "Wegovy is contraindicated in pregnancy. Weight loss offers no potential benefit to a pregnant patient and may result in fetal harm." Zepbound carries identical language.

Washout periods: how long to wait before conceiving

The required washout period depends on the drug's half-life — the time it takes for half the drug to be eliminated from the body. A general pharmacological principle is that it takes approximately 5 half-lives for a drug to be functionally cleared from the system.

The 2-month washout for semaglutide is explicitly stated in the Wegovy prescribing information, not a general guideline. This is because semaglutide's 7-day half-life means it takes approximately 5 weeks for the drug to clear — and the prescribing information adds a safety margin.

What about unplanned pregnancy?

Patients who discover they are pregnant while taking a GLP-1 medication should discontinue the drug immediately and contact their prescriber. The prescribing information recommends reporting pregnancies to the manufacturer's pregnancy registry (Novo Nordisk for semaglutide, Eli Lilly for tirzepatide). These registries help track outcomes and build the human safety database.

An unplanned pregnancy while on a GLP-1 does not automatically mean harm has occurred — the animal data establishes risk at clinically relevant exposures but cannot predict individual human outcomes. However, the drug should not be continued once pregnancy is confirmed.

Contraception during GLP-1 treatment

Patients of childbearing potential should use effective contraception during GLP-1 treatment. This is especially important with tirzepatide, which reduces the absorption of oral contraceptives:

• Tirzepatide reduces ethinylestradiol peak concentration (Cmax) by 59% and total exposure (AUC) by 21%. It also reduces norelgestromin Cmax by 55%. This can compromise oral contraceptive efficacy.

• The Zepbound prescribing information recommends switching to a non-oral contraceptive method or adding a barrier method for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase.

• Semaglutide does not appear to significantly affect oral contraceptive exposure at the same magnitude, so no specific contraceptive switching is recommended. However, GI side effects (vomiting) can functionally impair oral contraceptive absorption during dose escalation.

• IUDs, implants, and injectable contraceptives are not affected by GLP-1 medications because they bypass gastrointestinal absorption entirely.

Male partners: should they stop GLP-1 treatment?

Animal studies with semaglutide showed effects on male fertility at high doses, including reduced sperm counts and testicular abnormalities in rats. However, these effects occurred at exposures substantially higher than clinical doses, and the prescribing information does not currently recommend that male partners discontinue treatment before conception.

That said, some clinicians advise caution and suggest male partners discuss the timing with their prescriber, particularly if there are pre-existing fertility concerns. This is an area where the data is limited and clinical judgment varies.

GLP-1 and breastfeeding

The prescribing information for Wegovy and Zepbound recommends against use during breastfeeding due to insufficient data. It is not known whether semaglutide or tirzepatide are excreted in human breast milk, or whether the drugs affect milk production or the breastfed infant. Animal studies detected semaglutide in the milk of lactating rats.

The clinical decision to use GLP-1 medication during breastfeeding requires weighing the developmental and health benefits of breastfeeding against the mother's clinical need for treatment and any potential adverse effects on the breastfed infant. This is a conversation between the patient and their prescriber — not a decision that should be made based on telehealth marketing copy.

Fertility after GLP-1 treatment: the unintended benefit

There is an emerging clinical observation — sometimes called "Ozempic babies" in popular media — of increased fertility in patients who lose significant weight on GLP-1 medications. This is not a pharmacological effect of the drug itself but rather a consequence of weight loss. Obesity is associated with anovulation, polycystic ovary syndrome (PCOS), and reduced fertility. Losing 10-15% of body weight can restore ovulatory cycles and improve conception rates.

This means patients who were previously infertile or relying on obesity as a de facto contraceptive method may become fertile during GLP-1 treatment. This reinforces the importance of active contraception during treatment for any patient who does not want to become pregnant.